Using metabolomics to identify novel risk factors for lacunar stroke and vascular cognitive impairment

Wen Hui Ng[1], Elnara Aghakishiyeva[1], Hugh S. Markus[1], and Eric L. Harshfield[1]

Abstract

Lacunar stroke results from cerebral small vessel disease (SVD) and is a major cause of vascular dementia and cognitive decline. We aimed to evaluate the associations of circulating serum metabolites with lacunar stroke, neuroimaging markers of SVD, and cognition to help elucidate the pathogenesis of SVD.

In a unique clinical cohort of 1,456 magnetic resonance imaging (MRI)-confirmed lacunar stroke cases and 952 controls, we examined 250 metabolites measured at baseline using nuclear magnetic resonance (NMR) spectroscopy. We investigated the association between metabolites with lacunar stroke and its subtypes, presence of white matter hyperintensities and cerebral microbleeds, and vascular cognitive impairment using the Brief Memory and Executive Test (BMET).

We identified 211 metabolites (84%) that were significantly associated with lacunar stroke after correction for multiple testing, out of which 203 were significantly associated with isolated lacunar infarcts (ILI) and 207 with multiple lacunar infarcts or leukoaraiosis (MLI/LA). There were no significant associations of metabolites with MRI markers of SVD or total BMET score; however, five metabolites pertaining to lipoprotein concentrations, lipoprotein ratios, and glycolysis (S_HDL_L, S_HDL_P, S_HDL_PL, L_LDL_CE_pct, and lactate) were significantly associated with the BMET executive functioning/processing speed (EF/PS) subdomain.

We found associations of a wide range of metabolites with lacunar stroke and its subtypes, several of which were also associated with executive functioning and processing speed. These results emphasise the importance of metabolomics in unravelling metabolic pathways involved in the pathogenesis of lacunar stroke and SVD and cognitive decline.

Author affiliations:

[1] Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom

Correspondence to: Eric L. Harshfield, PhD

Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, R3, Box 83, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, United Kingdom

eh457@medschl.cam.ac.uk

Running title: Metabolomics in lacunar stroke

Keywords: cerebral small vessel disease; cognition; lacunar stroke; metabolomics; vascular cognitive impairment

Introduction

Cerebral small vessel disease (SVD) is a progressive cerebrovascular disorder affecting the small perforating arteries, arterioles, capillaries, and small veins in the brain.[1] These small vessels are crucial to the maintenance of adequate blood flow to the sub-surface brain structure and facilitate optimal functioning of the brain's most metabolically active white and deep grey matter networks.[1] SVD is a key mechanism linking stroke and dementia, particularly vascular dementia.[2] SVD is also responsible for lacunar stroke and most deep intracerebral haemorrhages, resulting in considerable public health burden.[3,4] The clinical consequences of SVD are diverse, ranging from subtle cognitive impairments and gait disturbances to severe cognitive decline and recurrent strokes.[5] SVD can be characterised by neuroimaging characteristics shown on MRI, including lacunar infarcts, cerebral microbleeds, white matter hyperintensities (WMH), perivascular spaces, and brain atrophy.[6]

SVD can be divided into amyloid-related SVD and non-amyloid-related sporadic subcortical SVD, which is usually related to hypertension. The latter subtype is the topic of this study. A number of pathological processes have been described in sporadic SVD, including a diffuse abnormality of the small vessels referred to as lipohyalinosis, and atheroma affecting both the perforating arteries themselves and the larger intracerebral arteries from which they arise. Early pathological studies suggested that there were two district types of sporadic SVD, one with single larger lacunar infarcts due to microatheroma, and one with multiple smaller lacunar infarcts due to lipohyalinosis.[7] Radiological studies have shown that the latter subtype is often associated with confluent white matter hyperintensities,[8] and differing cardiovascular risk profiles have been shown between the two subtypes.[9]

Despite its importance, the pathogenesis underlying SVD is currently not well understood, which is partly due to the difficulty in visualising and investigating such small vessels *in vivo* and the lack of attention given to SVD as an important mechanism in stroke until recently.[10] This has resulted in the absence of current beneficial treatments or preventive measures for SVD. Understanding the pathophysiology of SVD and identifying novel risk factors are crucial for guiding the development of targeted interventions aimed at preventing stroke and mitigating the progression of cognitive decline.

Metabolomics profiling, the high-throughput identification and precise quantification of small metabolic markers in biological samples, is a promising technique for identifying novel risk factors in SVD to better understand metabolic pathways underlying disease pathogenesis and enhance prediction of disease progression and severity.[11] This method uses advanced analytical techniques, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy, to identify and quantify metabolites with high sensitivity and specificity. The comprehensive metabolite measurements and detailed characterisation of metabolic phenotypes allows determination of metabolic arrangements underlying disease pathogenesis and discovery of therapeutic markers and identification of novel biomarkers to monitor and diagnose disease.[12] Metabolomics has been successfully applied in a number of cardiovascular and neurological diseases,[13,14] but there have been few studies in SVD. Previous studies have shown associations of metabolites with MRI features of SVD in a large community population[15] and in small cohort studies,[11,16] but there have been no metabolomics studies in large cohorts of lacunar stroke patients and there is limited data on the association of metabolites with vascular cognitive impairment. Studying metabolites could gain insights into biochemical activities and disease-related pathways within the body, providing insights into

molecular mechanisms underlying SVD and cognitive decline and potentially serve as useful biomarkers or therapeutic targets.

In this study, we compared metabolite concentrations in both lacunar stroke patients and stroke-free controls in two longitudinal prospectively recruited multicentre studies of MRI-confirmed lacunar stroke in the UK (DNA Lacunar 1 and 2). In addition, we analysed associations of metabolites with lacunar stroke subtypes, with imaging markers of SVD, and with cognition, allowing the detailed investigation of metabolic pathways underlying lacunar stroke and SVD.

Materials and methods

Study population

DNA Lacunar 1 (DL1) and DNA Lacunar 2 (DL2) are prospective studies of patients with MRI-confirmed lacunar stroke recruited from stroke centres throughout the UK. DL1 recruited 1,030 patients of European ancestry aged ≤70 years with lacunar stroke from 72 specialist stroke centres throughout the UK between 2002 and 2012.[17] DL2, for which recruitment is currently ongoing, had recruited 1,319 MRI-confirmed lacunar stroke patients as of July 2023 from 54 hospitals across the UK.[18] Both studies had the same inclusion criteria except that DL1 only recruited patients who had experienced a stroke prior to age 70. Lacunar stroke was identified based on the presence of a clinical lacunar syndrome with an anatomically compatible lesion on MRI, defined as a diffusion-weighted imaging (DWI) positive lesion for acute infarcts, and a cavitated lacune in an anatomically corresponding lesion for cases imaged >3 weeks after the acute event.[17] The median time from event to MRI was 5 days. Each patient underwent comprehensive stroke investigations including brain MRI, carotid artery imaging and ECG, as well as echocardiography where necessary. Exclusion criteria included stenosis >50% in the extracranial or intracranial cerebral vessels, history of carotid endarterectomy, high or moderate probability of cardioembolic stroke sources defined by the Trial of Org 10172 Acute Stroke Therapy (TOAST) classification criteria,[19] cortical infarcts on MRI, subcortical infarcts that are <15mm in diameter, a monogenic cause of stroke, or other specific causes of stroke.[17] All clinical histories and MRI scans were reviewed centrally by an experienced physician to confirm eligibility.

DL1 also recruited 1,973 unrelated hospital controls of European ancestry without cerebrovascular disease from general practices in the same geographical area by random sampling.[17] Both cases and controls completed standardised clinical assessments and a questionnaire. Brain MRI was not conducted for the controls. Blood was drawn from cases and controls, including serum and plasma, which was centrifuged immediately and stored at -80 °C.

DL1 was approved by the Multi-Centre Research Ethics Committee (04/MRE00/36). DL2 received approval from the East of England – Cambridge Central Research Ethics Committee (16/EE/0201). Informed consent was obtained from all participants in both studies.

Review of MRI

All MRI scans, which were performed clinically at each of the recruiting sites, were reviewed centrally to confirm eligibility. The number of lacunes were counted on fluid-attenuated inversion recovery (FLAIR) images, with a lacune defined as a round or ovoid subcortical fluid-filled cavity of 3-15 mm in diameter.[20] The number of cerebral microbleeds were counted using the Brain Observer Microbleed Rating Scale (BOMBS), with a microbleed defined as a focal area of very low intensity <10 mm in diameter.[21] The Fazekas scale was used to grade the extent of WMH on T2-FLAIR images.[20] In addition, the MRI scans were used to classify lacunar stroke cases into subtypes. Isolated lacunar infarcts (ILI) and multiple lacunar infarcts (MLI) were defined as 1 or >1 lacunar infarct, respectively, without confluent WMH, i.e. a grade <2 on the Fazekas scale. Leukoaraiosis (LA) was defined as having confluent WMH, i.e. a grade ≥2 on the Fazekas scale, with or without MLI. MLI and LA were combined in accordance with previous studies since they have a shared pathology.[22]

Cognitive assessment

Lacunar stroke cases from DL2 were assessed with the Brief Memory and Executive Test (BMET).[20,23] This is a short cognitive screening tool, designed and validated to be sensitive for the detection of vascular cognitive impairment (VCI) in SVD patients.[23] The test is freely available at www.bmet.info. It includes a number of subscores, each ranked on an age normative scale from 0 to 2, which are used to form a total score that ranges from 0 to 16.[23] A BMET total score of ≤13 has been previously validated to define the presence of VCI.[23] The test performance can be subdivided into two major cognitive domain clusters,

orientation/memory (O/M) and executive functioning/processing speed (EF/PS), each with a score ranging from 0 to 8. The O/M subdomain score was calculated from the tasks for orientation, five-item repetition, five-item recall, and five-item recognition memory, while the EF/PS subdomain score was calculated from the tasks for letter-number matching, motor sequencing, letter sequencing, and number-letter sequencing.[23]

Metabolomics profiling

Serum samples for 2,500 participants were selected from DL1 and DL2, of whom 673 were cases from DL1, 827 were cases from DL2, and 1,000 were controls from DL1. All selected cases had lacunar stroke confirmed on central review of imaging, while cases that were ineligible on central review or had withdrawn from the study were excluded. Serum samples were prioritised for selection amongst participants that had sufficient sample volume (minimum 350 µL). Samples in 0.5 mL tubes were transferred from a variety of storage trays and boxes in -80 °C freezers to twenty-seven 96-well microtube racks. Samples were arranged on each rack with up to 25 DL1 cases, 31 DL2 cases, and 38 DL1 controls, with 2 empty wells for QC samples.

Metabolic biomarker profiling of patient and control serum samples was performed at Nightingale Health's laboratories in Finland in September 2023. Serum samples were shipped on dry ice and high-throughput proton nuclear magnetic resonance (NMR) spectroscopy was used to obtain measurements of 250 metabolites for each sample with high precision and accuracy.[24] All samples were processed on a single spectrometer. Data processing involved advanced proprietary algorithms that translate the NMR spectral data into absolute quantifications of metabolites.[24] The platform included a wide range of biomarkers including amino acids, apolipoproteins, cholesterol and cholesteryl esters, fatty acids, phospholipids, triglycerides, and detailed measurements of lipid concentrations and compositions within 14 different lipoprotein subclasses.[24] The metabolites and their classifications are listed in **Supplementary Table 1**. Metabolic pathways relevant to chronic diseases and overall health were also provided.

Statistical analyses

To ensure approximately normal distributions, prior to statistical analyses a generalised log transformation was applied to each metabolite and the concentrations were rescaled using mean

centring and dividing by the standard deviation of each metabolite across participants. Nightingale Health confirmed that due to the high repeatability and negligible batch effects with their metabolic biomarker profiling platform and that all samples from DL1 and DL2 were analysed on a single mass spectrometer, it was not necessary to correct the metabolite levels for batch effects.

Presence of confluent WMH was defined as a Fazekas grade ≥2, and presence of cerebral microbleeds was defined as ≥1 cerebral microbleed. The BMET total score was recategorized so that a total score ≤13 indicated evidence of vascular cognitive impairment while a total score >13 indicated no evidence of vascular cognitive impairment. Age-normalised scores for the BMET O/M and EF/PS subdomains were analysed as continuous outcomes. A lower score on each subdomain normally indicates worse cognition, but the direction was reversed so that the direction of effect would be consistent with the other outcomes, i.e. so that a higher score on each subdomain indicated evidence of cognitive impairment.

In our primary analyses, we studied the association of metabolites with all lacunar stroke and with the ILI and MLI/LA subtypes by constructing logistic regression models with adjustment for age and sex. Within lacunar stroke cases (i.e. excluding controls), we also analysed the association of each metabolite with presence of WMH and cerebral microbleeds and with BMET total score using logistic regression with adjustment for age and sex. We constructed linear regression models with adjustment for age and sex to analyse the association of each metabolite with the BMET O/M and EF/PS subdomain scores. We calculated odds ratios or risk ratios for each association and produced circular bar plots to visualise the results.

As sensitivity analyses, we conducted regression analyses for the association of each metabolite with the above outcomes with adjustment for age, sex, hypertension, smoking status, alcohol consumption, body mass index, hyperlipidaemia, and type 2 diabetes.

We also conducted a principal component analysis (PCA) of metabolite levels to observe clustering according to the amount of variance in metabolite concentrations captured by each principal component. We analysed the association of the top principal components, which explained the greatest proportion of the variance in metabolite concentrations, with each of the above outcomes with adjustment for age and sex.

Analyses were conducted in R v4.4.1. A false discovery rate (FDR) threshold of 5% was used to account for testing associations with 250 metabolites for each outcome.

Data availability

Recruitment to the DNA Lacunar 2 study is ongoing. Investigators may request access to anonymized individual patient data after recruitment to the study is completed. The authors will share the data with qualified investigators whose proposal of data use has been approved by an independent review committee.

Results

Participant characteristics

Metabolomics measurements that passed quality control were returned for 2,408 participants. Out of these, 645 participants were lacunar stroke cases from DL1, 811 were lacunar stroke cases from DL2, and 952 were controls from DL1. Cases from DL1 and DL2 were combined. Details of the characteristics of participants including in this analysis are summarised in **Table 1**.

Lacunar stroke cases were slightly older than controls (**Table 1a**), with a mean age of 61.92 (SD 11.54) for cases and 57.49 (SD 6.25) for controls. 66.1% of cases and 62.5% of controls were male. Cases were significantly more likely to have hypertension (71.8% vs 46.5%), hyperlipidaemia (65.7% vs 50.9%), and type 2 diabetes (19.4% vs 6.5%) than controls, and cases were more likely to smoke (28.8% vs 13.8%) but less likely to consume alcohol (66.5% vs 79.5%). Cases also had a slightly higher BMI on average, with a mean BMI of 28.45 kg/m^2 (SD 6.09) for cases and 27.38 kg/m^2 (SD 5.26) for controls.

Within lacunar stroke subtypes, similar trends were observed for cases with ILI and cases with MLI/LA when compared to controls (**Table 1b**). However, cases with MLI/LA were slightly older than cases with ILI, with a mean age of 64.50 (SD 11.35) for MLI/LA and 58.35 (10.86) for ILI. There was also a higher proportion of hypertension (78.0% vs 63.3%) and type 2 diabetes (22.1% vs 15.7%) and a lower proportion of alcohol consumption (62.5% vs 71.9%) in cases with MLI/LA compared to ILI.

Cerebral microbleeds were much more common in cases with MLI/LA than in cases with ILI (41.7% vs 9.7%) (**Table 1c**). Cases with MLI/LA had worse cognition on average, with a

BMET total score of 12.62 (SD 3.65) for cases with MLI/LA and 13.95 (SD 2.59) for cases with ILI. Cases with MLI/LA also had worse cognitive scores on the O/M and EF/PS subdomains than cases with ILI.

Associations of metabolites with lacunar stroke

We found that 211 metabolites out of 250 (84%) were significantly associated with lacunar stroke at an FDR-corrected threshold of $P < 0.05$ (**Figs. 1** and **2**, **Supplementary Fig. 1**, and **Supplementary Table 2**). Lower levels of amino acids, ketone bodies, apolipoproteins, fatty acids, cholesterol and cholesteryl esters, multiple lipoprotein subclasses, and multiple relative lipoprotein lipid concentrations, and higher levels of acetoacetate, creatinine, fluid balance, glucose, glycoprotein acetyls (GlycA), 3-Hydroxybutyrate, and other relative lipoprotein lipid concentrations were associated with increased risk of lacunar stroke. Similar associations were also observed within subsets of lacunar stroke cases with ILI and with MLI/LA compared to controls (**Supplementary Figs. 2** and **3** and **Supplementary Table 2**).

In sensitivity analyses adjusted for additional vascular risk factors and potential confounders, there were also 211 metabolites that were significantly associated with lacunar stroke after FDR correction, with a high degree of overlap with the models that were significantly associated with lacunar stroke in the primary analysis (**Supplementary Table 3**). However, there were 28 metabolites, mostly from lipoprotein subclasses, that were only associated with lacunar stroke in the fully adjusted model, and 28 metabolites, mostly from lipoprotein subclasses and relative lipoprotein lipid concentrations, that were only associated with lacunar stroke in the basic adjustment model.

Associations of principal components of metabolites with lacunar stroke

We conducted a principal component analysis on the concentrations of 250 metabolites. A scree plot (**Supplementary Fig. 4a**) showed that the first four principal components explained more than 75% of the variance in the metabolite concentrations and the first 22 principal components explained more than 95% of the variance. A scatter plot of the matrix loadings (**Supplementary Fig. 4b**) showed that there was variability in metabolite levels by the overall metabolite classification according to the first and second principal components. Fourteen of the first 22 principal components had significant associations with lacunar stroke after

correction for multiple testing (**Supplementary Fig. 5** and **Supplementary Table 4**). Similar associations were also observed for cases with ILI and with MLI/LA compared to controls.

Associations of metabolites with neuroimaging markers of SVD

Within the 1,456 lacunar stroke cases, we conducted cross-sectional univariate analyses of metabolites with two MRI markers of SVD, namely the presence of confluent WMH and cerebral microbleeds, with adjustment for age and sex (**Fig. 2**).

There were 75 metabolites that were associated with WMH and 73 metabolites that were associated with cerebral microbleeds, but none of the associations remained statistically significant after correction for multiple testing. The full association statistics adjusted for age and sex and adjusted for additional vascular risk factors are provided in **Supplementary Tables 5** and **6**, respectively.

Associations of metabolites with cognitive impairment

Within the 743 lacunar stroke cases from DL2 whom had completed the BMET, the association of 250 baseline metabolic measures with vascular cognitive impairment, defined as a total BMET score of ≤ 13, and with scores on the O/M and EF/PS subdomains, was assessed in cross-sectional univariate analyses adjusted for age and sex (**Fig. 2**).

There were no metabolites that had statistically significant associations with total BMET score after correction for multiple testing. However, five metabolites pertaining to lipoprotein concentrations, lipoprotein ratios, and glycolysis (S_HDL_L, S_HDL_P, S_HDL_PL, L_LDL_CE_pct, and lactate) were significantly associated with the EF/PS subdomain. Full association statistics are provided in **Supplementary Tables 7** and **8**.

Statistically significant associations across analyses

The metabolites that had statistically significant associations across multiple analyses are summarised in **Supplementary Table 9**. Metabolites were identified that had statistically significant associations with at least two out of three of the following: (1) lacunar stroke cases or cases with ILI or MLI/LA; (2) presence of white matter hyperintensities or microbleeds; and (3) vascular cognitive impairment according to the BMET total score or scores on the O/M or EF/PS subdomains. At an unadjusted significance threshold of $P < 0.05$, there were 137

metabolites with significant associations. However, after correction for multiple testing, only four metabolites (S_HDL_L, S_HDL_P, S_HDL_PL, and lactate) had statistically significant associations after correction for multiple testing.

Discussion

In this metabolomics study of 2,408 lacunar stroke cases and controls, we identified 211 metabolites that were significantly associated with lacunar stroke, most of which were also associated with both ILI and MLI/LA. There were no statistically significant associations with neuroimaging markers of SVD or vascular cognitive impairment within lacunar stroke cases, but five metabolites pertaining to lipoprotein concentrations, lipoprotein ratios, and glycolysis were significantly associated with the BMET EF/PS subdomain. Lower concentrations of total lipids in small HDL (S_HDL_L), the concentration of small HDL particles (S_HDL_P), phospholipids in small HDL (S_HDL_PL), and the percentage of cholesteryl esters to total lipids in large LDL (L_LDL_CE_pct), and higher concentrations of lactate were associated with worse executive function and processing speed. These findings highlight possible shared underlying metabolic pathways and the complex interplay between metabolites in affecting lacunar stroke and cognitive decline.

A previous study identified consistent associations of these metabolites in UK Biobank participants.[15] It showed that lower levels of S_HDL_L, S_HDL_P, and L_LDL_CE_pct were associated with increased white matter structural damage on diffusion tensor imaging and increased risk of stroke and dementia.[15] Another study also showed that S_HDL_P was associated with all-cause dementia and vascular dementia, and that L_LDL_CE_pct was associated with all-cause dementia and Alzheimer's disease.[29] The present study adds to this knowledge by showing that these metabolites are also associated with worse executive function and processing speed in individuals who have experienced a lacunar stroke.

Studies have also developed metabolite scores, such as the MetaboHealth score and a metabolic aging score, which have used a combination of metabolites for prediction of all-cause and cause-specific mortality, neurocognitive function and functional independence, and biological aging.[25–27] Lactate was significantly associated with each out of these outcomes and was included in the scores in each study. Our study showed that lactate is also associated with lacunar stroke, ILI and MLI/LA, and worse executive function and processing speed. Lactate

plays a significant role in many physiological and pathological processes, including regulation of energy metabolism, immune response, and memory formation, and is thought to potentially be a viable target for treatment of cardiovascular and inflammatory diseases.[28]

This study has several important strengths. The analyses were conducted in a unique population, a clinical cohort of MRI-confirmed lacunar stroke cases and controls, to examine the role that metabolites play in lacunar stroke onset and disease progression. Numerous metabolites were identified that are associated with lacunar stroke, highlighting the importance of metabolic pathways in the disease pathophysiology, and indicating areas for further research in risk prediction and screening for potential therapeutic targets.

There are also a few limitations. First, neuroimaging markers and cognitive scores were only available in DL2 cases, so due to the smaller sample size, these analyses had less power to detect statistically significant associations. Second, an FDR threshold was applied to correct for multiple testing and reduce the likelihood of identifying false-positive associations, but this may have inadvertently discounted some biologically and clinically meaningful associations that did not reach the threshold for statistical significance. Third, the analyses were cross-sectional, so it is not possible to determine whether the identified associations are causal. Obtaining follow-up data on clinical endpoints will enable longitudinal analyses to be conducted to evaluate the effect of changes in metabolite levels on long-term risk of cerebrovascular and neurological conditions to better understand disease progression over time. Additionally, conducting genome-wide association analyses of metabolite concentrations in DL1 and DL2 would enable Mendelian randomization analyses to be performed to evaluate whether the identified associations from this study are likely to be causal.

In this study, we identified 211 metabolites that were significantly associated with lacunar stroke, most of which were also associated with lacunar stroke subtypes, and we identified five metabolites pertaining to lipoprotein concentrations, lipoprotein ratios, and glycolysis that were associated with lower execution function and processing speed. Although further research is needed to validate the findings and discern the biochemical pathways through which metabolites impact lacunar stroke outcomes, this study provides valuable evidence to help uncover novel metabolic markers of lacunar stroke and SVD. Follow-up studies on the metabolites with strong and consistent associations could uncover potentially causal metabolites or help to develop a metabolite fingerprint that evaluates the risk of SVD and cognitive decline through clinical blood tests.

Acknowledgements

Members of the DNA Lacunar 1 and 2 Coordinating Centres, Recruitment Centres, and Collaborators are listed in Supplementary Appendix 1.

For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Funding

This research was supported by the British Heart Foundation (RG/F/22/110052). Infrastructural support was provided by the Cambridge British Heart Foundation Centre of Research Excellence (RE/18/1/34212; RE/24/130011) and the Cambridge University Hospitals National Institute for Health and Care Research (NIHR) Biomedical Research Centre (NIHR203312). ELH was supported by the Alzheimer's Society (AS-RF-21-017).

Collection of the UK Young Lacunar Stroke DNA Study (DNA Lacunar 1) was primarily supported by the Wellcome Trust (WT072952) with additional support from the Stroke Association (TSA 2010/01). Genotyping of the DNA Lacunar 1 samples was supported by a Stroke Association grant (TSA 2013/01).

Collection and genotyping of the UK Young Lacunar Stroke DNA Study 2 (DNA Lacunar 2) was supported by British Heart Foundation Programme Grants (RG/16/4/32218 and RG/F/22/110052).

The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Competing interests

The authors report no competing interests.

Appendix 1

Members of DNA Lacunar 1 and 2 Coordinating Centres and Recruiting Centres

DNA Lacunar 1 Study Managers: Josie Monaghan; Alan Zanich, Samantha Febrey, Eithne Smith, Jenny Lennon, St George's University of London

DNA Lacunar 1 Participating Centres (number of enrolled patients per centre; local investigators): Aberdeen Royal Infirmary, Aberdeen (12; Mary Macleod). Addenbrooke's Hospital, Cambridge (54; Jean-Claude Baron, Elizabeth Warburton, Diana J Day, Julie White). Airedale General Hospital, Steeton (4; Samantha Mawer). Barnsley Hospital, Barnsley (3; Mohammad Albazzaz, Pravin Torane, Keith Elliott, Kay Hawley). Bart's and the London, London (2; Patrick Gompertz). Basingstoke and North Hampshire Hospital, Basingstoke (13; Elio Giallombardo, Deborah Dellafera). Blackpool Victoria Hospital, Blackpool (11; Mark O'Donnell). Bradford Royal Infirmary, Bradford (1; Chris Patterson). Bristol Royal Infirmary, Bristol (8; Sarah Caine). Charing Cross Hospital, London (12; Pankaj Sharma). Cheltenham General and Gloucester Royal Hospitals, Cheltenham and Gloucester (10; Dipankar Dutta). Chesterfield Royal Hospital, Chesterfield (4; Sunil Punnoose, Mahmud Sajid). Countess of Chester Hospital, Chester (22; Kausik Chatterjee). Derriford Hospital, Plymouth (4; Azlisham Mohd Nor). Dorset County Hospital NHS Foundation Trust, Dorchester (6; Rob Williams). East Kent Hospitals University NHS Foundation Trust, Kent (22; Hardeep Baht, Guna Gunathilagan). Eastbourne District General Hospital, Eastbourne (4; Conrad Athulathmudali). Frenchay Hospital, Bristol (1; Neil Baldwin). Frimley Park Hospital NHS Foundation Trust, Frimley (6; Brian Clarke). Guy's and St Thomas' Hospital, London (14; Tony Rudd). Institute of Neurology, London (25; Martin Brown). James Paget University Hospital, Great Yarmouth (1; Peter Harrison). King's College Hospital, London (16; Lalit Kalra). Leeds Teaching Hospitals NHS Trust, London (125; Ahamad Hassan). Leicester General Hospital and Royal Infirmary, Leicester (9; Tom Robinson, Amit Mistri). Luton and Dunstable NHSFT University Hospital, Luton (16; Lakshmanan Sekaran, Sakthivel Sethuraman, Frances Justin). Maidstone andTunbridge Wells NHS Trust (3; Peter Maskell). Mayday University Hospital, Croydon (14; Enas Lawrence). Medway Maritime Hospital, Gillingham (5; Sam Sanmuganathan). Milton Keynes Hospital, Milton Keynes (1; Yaw Duodu). Musgrove Park Hospital, Taunton (9; Malik Hussain). Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne (12; Gary Ford).

Ninewells Hospital, Dundee (5; Ronald MacWalter). North Devon District Hospital, Barnstaple (8; Mervyn Dent). Nottingham University Hospitals, Nottingham (17; Philip Bath, Fiona Hammonds). Perth Royal Infirmary, Perth (2; Stuart Johnston). Peterborough City Hospital, Peterborough (1; Peter Owusu-Agyei). Queen Elizabeth Hospital, Gateshead (5; Tim Cassidy, Maria Bokhari). Radcliffe Infirmary, Oxford (5; Peter Rothwell). Rochdale Infirmary, Rochdale (4; Robert Namushi). Rotherham General Hospital, Rotherham (1; James Okwera). Royal Cornwall Hospitals NHS Trust, Truro (11; Frances Harrington, Gillian Courtauld). Royal Devon and Exeter Hospital, Exeter (22; Martin James). Royal Hallamshire Hospital, Sheffield (1; Graham Venables). Royal Liverpool University Hospital and Broadgreen Hospital, Liverpool (9; Aravind Manoj). Royal Preston Hospital, Preston (18; Shuja Punekar). Royal Surrey County Hospital, Guildford (23; Adrian Blight, Kath Pasco). Royal Sussex County Hospital, Brighton (14; Chakravarthi Rajkumar, Joanna Breeds). Royal United Hospital, Bath (6; Louise Shaw, Barbara Madigan). Salford Royal Hospital, Salford (16; Jane Molloy). Southampton General Hospital, Southampton (1; Giles Durward). Southend Hospital, Westcliff-on-Sea (26; Paul Guyler). Southern General Hospital, Glasgow (34; Keith Muir, Wilma Smith). St George's Hospital, London (108; Hugh Markus). St Helier Hospital, Carshalton (10; Val Jones). Stepping Hill Hospital, Stockport (4; Shivakumar Krishnamoorthy). Sunderland Royal Hospital, Sunderland (1; Nikhil Majumdar). The Royal Bournemouth Hospital, Bournemouth (15; Damian Jenkinson). The Walton Centre, Liverpool (15; Richard White). Torbay Hospital, Torquay (19; Debs Kelly). University Hospital Aintree, Liverpool (19; Ramesh Durairaj). University Hospital of North Staffordshire, Stoke-on-trent (16; David Wilcock). Wansbeck General Hospital and North Tyneside Hospital, Ashington and North Shields (6; Christopher Price). West Cumberland Hospital, Whitehaven (6; Olu Orugun, Rachel Glover). West Hertfordshire Hospital, Watford (20; David Collas). Western General Hospital, Edinburgh (12; Cathie Sudlow). Western Infirmary, Glasgow (33; Kennedy R. Lees, Jesse Dawson). Wycombe Hospital and Stoke Mandeville, High Wycombe (20; Dennis Briley and Matthew Burn). Yeovil District Hospital, Yeovil (46; Khalid Rashed). York Teaching Hospital, York (1; John Coyle).

DNA Lacunar 2 Coordinating Centre: Chief Investigator: Hugh Markus; Trial Coordinators: Rebecca Dowden, Laurence Loubiere, Elnara Aghakishiyeva; Case Reviewer: Lupei Cai.

DNA Lacunar 2 Recruiting Centres (local investigator, number of recruited participants as of 31 January 2025): Addenbrookes Hospital (Hugh Markus, 299), James Paget Hospital (Carlo Canepa, 3), Peterborough City Hospital (Santhosh Subramonian, 13), North Middlesex

Hospital (Robert Luder, 12), Royal Stoke Hospital (Janaka Weerathunga, 88), Royal London Hospital (Farhad Huwez, 21), West Suffolk Hospital (Abul Azim, 89), Watford General Hospital (Mohit Bhandari, 99), Royal Cornwall Hospital (Katja Adie, 20), New Cross Hospital, Wolverhampton (Nasar Ahmad, 34), Princess Royal University Hospital, Telford (Uttam Sinha, 2), King's Mill Hospital (Jahanzeb Rehan, 27), King's College Hospital (James Teo, 42), Queen Elizabeth Hospital, King's Lynn (Umesh Rai, 4), Countess of Chester Hospital (Kausik Chatterjee, 23), Leeds General Infirmary (Ahamad Hassan, 53), Royal Hallamshire Hospital (Aaizza Naqvi, 18), Wirral University Teaching Hospital (Ruth Davies, 0), University Hospital of North Tees (Ijaz Anwar, 12), Lister Hospital (Aparna Pusalkar, 4), Royal Bournemouth Hospital (Kamy Thavansan, 32), Royal Hampshire County Hospital (Nigel Smyth, 14), Derriford Hospital, Plymouth (Azlisham Mohd Nor, 25), Torbay Hospital (Biju Bhaskaran, 2), Pinderfields Hospital (Prabal Datta, 10), Queen's Hospital, Havering (Abhijit Chaudhuri, 0), Royal Devon and Exeter Hospital (Martin James, 15), University College Hospital (David Werring, 84), Nottingham City Hospital (Kailash Krishnan, 28), Salford Royal Hospital (Dwaipayan Sen, 11), James Cook University Hospital, South Tees (Samer Al-Hussayni, 31), University Hospital of North Durham (Revin Thomas, 52), Yeovil District Hospital (Khalid Rashed, 63), St Peter's Hospital (Brendan Affley, 29), Sandwell General Hospital (David Gull, 21), Guys and St Thomas' Hospital (Ajay Bhalla, 48), Royal Sussex County Hospital (Chakravarthi Rajkumar, 1), Southampton General Hospital (Emma Battersby-Wood, 31), Doncaster Royal Infirmary (Dinesh Chada, 26), St George's Hospital (Usman Khan, 123), Wycombe Hospital (Matthew Burn, 20), Musgrove Park Hospital (Malik Hussain, 37), Scunthorpe General Hospital (Amit Banerjee, 3), Ipswich Hospital (Sajid Alam, 17), Southend University Hospital (Paul Guyler, 12), Gloucestershire Royal Hospital (Dipankar Dutta, 23), Queen Elizabeth The Queen Mother Hospital, Margate (Saidu Abubakar, 9), Colchester General Hospital (Rajesh Saksena, 34), Royal Derby Hospital (Tim England, 5), Croydon University Hospital (Enas Lawrence, 66), Norfolk and Norwich University Hospital (Kneale Metcalf, 12), Leicester Royal Infirmary (Amit Mistri, 16), William Harvey Hospital (Ibrahim Balogun, 5), Medway Maritime Hospital (Samuel Sanmuganathan, 5), Kent and Canterbury Hospital (Saidu Abubakar, 16), Sunderland Royal Hospital (Naweed Sattar, 18), University Hospital Llandough (Benjamin Jelley, 11), Cheltenham General Hospital (Dipankar Dutta, 0), Royal Victoria Infirmary (Akif Gani, 16), University Hospital Coventry & Warwickshire (Munib Mirza, 16), Fairfield General Hospital (Narayanamoorthi Saravanan, 14), Milton Keynes University Hospital (Janet Costa, 9), Royal Blackburn Hospital (Anand Nair, 1), Royal Present Hospital (Hedley Emsley, 13), Stepping Hill Hospital (Appukuttan

Suman, 6), Royal Albert Edward Infirmary (Habib Rehman, 12), Broomfield Hospital (Ramanathan Kirthivasan, 34), Basildon University Hospital (Jigisha Amin, 1), Homerton University Hospital (Thomas Harrison, 0), Queen Elizabeth Hospital, Gateshead (Louise Southern), and Southmead Hospital (Sandeep Buddha, 0).

References

1. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol*. 2019;18(7):684-696. doi:10.1016/S1474-4422(19)30079-1

2. Haffner C, Malik R, Dichgans M. Genetic factors in cerebral small vessel disease and their impact on stroke and dementia. *J Cereb Blood Flow Metab*. 2016;36(1):158-171. doi:10.1038/jcbfm.2015.71

3. Markus HS, de Leeuw FE. Cerebral small vessel disease: recent advances and future directions. *Int J Stroke*. 2022;18(1):4-14. doi:10.1177/17474930221144911

4. Lam BYK, Cai Y, Akinyemi R, et al. The global burden of cerebral small vessel disease in low- and middle-income countries: a systematic review and meta-analysis. *Int J Stroke*. 2022;18(1):15-27. doi:10.1177/17474930221137019

5. Markus H. Stroke: causes and clinical features. *Medicine (Baltimore)*. 2016;44(9):515-520. doi:10.1016/j.mpmed.2016.06.006

6. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease—advances since 2013. *Lancet Neurol*. 2023;22(7):602-618. doi:10.1016/S1474-4422(23)00131-X

7. Fisher CM. The arterial lesions underlying lacunes. *Acta Neuropathol*. 1969;12(1):1-15. doi:10.1007/BF00685305

8. Boiten J, Lodder J, Kessels F. Two clinically distinct lacunar infarct entities? A hypothesis. *Stroke*. 1993;24(5):652-656. doi:10.1161/01.STR.24.5.652

9. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. *J Neurol Neurosurg Psychiatry*. 2007;78(7):702-706. doi:10.1136/jnnp.2006.103549

10. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel

disease: insights from neuroimaging. *Lancet Neurol*. 2013;12(5):483-497. doi:10.1016/S1474-4422(13)70060-7

11. Harshfield EL, Sands CJ, Tuladhar AM, de Leeuw FE, Lewis MR, Markus HS. Metabolomic profiling in small vessel disease identifies multiple associations with disease severity. *Brain*. 2022;145(7):2461-2471. doi:10.1093/brain/awac041

12. Trivedi DK, Hollywood KA, Goodacre R. Metabolomics for the masses: the future of metabolomics in a personalized world. *New Horizons Transl Med*. 2017;3(6):294-305. doi:10.1016/j.nhtm.2017.06.001

13. Iida M, Harada S, Takebayashi T. Application of metabolomics to epidemiological studies of atherosclerosis and cardiovascular disease. *J Atheroscler Thromb*. 2019;26(9):747-757. doi:10.5551/jat.RV17036

14. Jiang Y, Zhu Z, Shi J, et al. Metabolomics in the development and progression of dementia: a systematic review. *Front Neurosci*. 2019;13:343. doi:10.3389/fnins.2019.00343

15. Harshfield EL, Markus HS. Association of baseline metabolomic profiles with incident stroke and dementia and with imaging markers of cerebral small vessel disease. *Neurology*. 2023;101(5):e489-e501. doi:10.1212/WNL.0000000000207458

16. Li D, Misialek JR, Jack CR, et al. Plasma metabolites associated with brain MRI measures of neurodegeneration in older adults in the Atherosclerosis Risk in Communities–Neurocognitive Study (ARIC-NCS). *Int J Mol Sci*. 2019;20(7):1744. doi:10.3390/ijms20071744

17. Kilarski LL, Rutten-Jacobs LCA, Bevan S, et al. Prevalence of CADASIL and Fabry disease in a cohort of MRI defined younger onset lacunar stroke. *PLoS One*. 2015;10(8):e0136352. doi:10.1371/journal.pone.0136352

18. Traylor M, Persyn E, Tomppo L, et al. Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies. *Lancet Neurol*. 2021;20(5):351-361. doi:10.1016/S1474-4422(21)00031-4

19. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993;24(1):35-41. doi:10.1161/01.STR.24.1.35

20. Ohlmeier L, Nannoni S, Pallucca C, Brown RB, Loubiere L, Markus HS. Prevalence of,

and risk factors for, cognitive impairment in lacunar stroke. *Int J Stroke*. 2022;18(1):62-69. doi:10.1177/17474930211064965

21. Nannoni S, Ohlmeier L, Brown RB, Morris RG, Mackinnon AD, Markus HS. Cognitive impact of cerebral microbleeds in patients with symptomatic cerebral small vessel disease. *Int J Stroke*. 2021;17(4):415-424. doi:10.1177/17474930211012837

22. Traylor M, Bevan S, Baron JC, Hassan A, Lewis CM, Markus HS. Genetic architecture of lacunar stroke. *Stroke*. 2015;46(9):2407-2412. doi:10.1161/STROKEAHA.115.009485

23. Brookes RL, Hollocks MJ, Khan U, Morris RG, Markus HS. The Brief Memory and Executive Test (BMET) for detecting vascular cognitive impairment in small vessel disease: a validation study. *BMC Med*. 2015;13(1):51. doi:10.1186/s12916-015-0290-y

24. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet*. 2015;8(1):192-206. doi:10.1161/CIRCGENETICS.114.000216

25. Deelen J, Kettunen J, Fischer K, et al. A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. *Nat Commun*. 2019;10(1):3346. doi:10.1038/s41467-019-11311-9

26. Zonneveld MH, Kuhaili N Al, Mooijaart SP, et al. Increased 1H-NMR metabolomics-based health score associates with declined cognitive performance and functional independence in older adults at risk of cardiovascular disease. *medRxiv*. 2023;2023.12.21. doi:10.1101/2023.12.21.23300037

27. Zhang S, Wang Z, Wang Y, et al. A metabolomic profile of biological aging in 250,341 individuals from the UK Biobank. *Nat Commun*. 2024;15(1):8081. doi:10.1038/s41467-024-52310-9

28. Li X, Yang Y, Zhang B, et al. Lactate metabolism in human health and disease. *Signal Transduct Target Ther*. 2022;7(1):305. doi:10.1038/s41392-022-01151-3

29. Huang SY, Zhang YR, Yang L, et al. Circulating metabolites and risk of incident dementia: a prospective cohort study. *J Neurochem*. 2023;167(5):668-679. doi:10.1111/jnc.15997

Figure legends

Figure 1 Circular bar plot showing the results of cross-sectional univariate analyses for the association between 250 metabolic biomarkers and lacunar stroke. Abbreviations: FDR: false discovery rate; SD: standard deviation. Odds ratios with 95% confidence intervals for the association with lacunar stroke versus controls are presented per 1-SD increase in metabolite concentration with adjustment for age, sex, hypertension, and recruitment centre. Associations shown in red indicate increased odds of lacunar stroke, and in blue indicate reduced odds of lacunar stroke. Associations significant at an FDR-corrected $P < 0.05$ are indicated with an asterisk (*) alongside the names of the respective metabolites.

Figure 2 Heat map showing the results of cross-sectional univariate analyses for the association between 250 metabolic biomarkers and lacunar stroke, MRI markers, and cognitive impairment. (a) Main metabolites. (b) Lipoprotein subclasses and relative lipoprotein lipid concentrations. Abbreviations: BMET: Brief Memory and Executive Test; EF/PS: executive functioning/processing speed; FDR: false discovery rate; ILI: isolated lacunar infarcts; MLI: multiple lacunar infarcts; LA: leukoaraiosis; O/M: orientation/memory; SD: standard deviation; SVD: small vessel disease; WMH: white matter hyperintensities. Beta estimates and *P*-values were obtained from logistic or linear regression models adjusted for age and sex. Colours show magnitude and direction of *P*-value for association of metabolite with each outcome. Associations with beta coefficients >1 are represented in red, and associations with beta coefficients <1 are shown in blue. Associations significant at an FDR-corrected $P < 0.05$ are indicated with two asterisks (**) and associations significant at an unadjusted $P < 0.05$ are indicated with a single asterisk (*).

Tables

Table 1 Characteristics of participants from DNA Lacunar 1 and 2 with metabolomics data

a) Demographics and vascular risk factors in lacunar stroke cases and controls

Risk factors	Cases (n=1,456)	Controls (n=952)	*P*-value
Age at recruitment (years)	61.92 (11.54)	57.49 (6.25)	<0.001
Male sex	962 (66.1%)	595 (62.5%)	0.0803
Hypertension	1,046 (71.8%)	443 (46.5%)	<0.001
Hyperlipidaemia	955 (65.7%)	479 (50.9%)	<0.001
Type 2 diabetes	283 (19.4%)	62 (6.5%)	<0.001
Current smoker	419 (28.8%)	131 (13.8%)	<0.001
Alcohol consumption	966 (66.5%)	749 (79.5%)	<0.001
Body mass index (kg/m^2)	28.45 (6.09)	27.38 (5.26)	<0.001

b) Demographics and vascular risk factors in lacunar stroke subtypes (ILI and MLI/LA) and comparison with controls

Risk factors	ILI (n=610)	*P*-value	MLI/LA (n=842)	*P*-value
Age at recruitment (years)	58.35 (10.86)	0.0747	64.50 (11.35)	<0.001
Male sex	397 (65.1%)	0.3269	563 (66.9%)	0.0602
Hypertension	386 (63.3%)	<0.001	657 (78.0%)	<0.001
Hyperlipidaemia	391 (64.1%)	<0.001	561 (66.8%)	<0.001
Type 2 diabetes	96 (15.7%)	<0.001	186 (22.1%)	<0.001
Current smoker	179 (29.3%)	<0.001	238 (28.3%)	<0.001
Alcohol consumption	438 (71.9%)	0.0007	525 (62.5%)	<0.001
Body mass index (kg/m^2)	28.83 (6.28)	<0.001	28.18 (5.95)	0.0028

c) Neuroimaging markers and cognition in lacunar stroke cases and subtypes (ILI and MLI/LA)

Risk factors	Cases (n=1,456)	ILI (n=610)	MLI/LA (n=842)
WMH (Fazekas score ≥2)	591 (40.6%)	4 (0.7%)	587 (69.7%)
Presence of cerebral microbleeds	214 (29.8%)	26 (9.7%)	188 (41.7%)
BMET total score	13.13 (3.35)	13.95 (2.59)	12.62 (3.65)
BMET O/M subdomain	6.55 (1.88)	6.92 (1.58)	6.32 (2.02)
BMET EF/PS subdomain	6.67 (1.98)	7.06 (1.62)	6.43 (2.14)

Abbreviations: BMET: Brief Memory and Executive Test; EF/PS: executive functioning/processing speed; ILI: isolated lacunar infarcts; MLI: multiple lacunar infarcts; LA: leukoaraiosis; O/M: orientation/memory; SD: standard deviation; WMH: white matter hyperintensities.
Mean and standard deviation (SD) are shown for continuous variables, while frequency and percentage are shown for categorical variables.
P-values for *t*-tests are reported for continuous variables and *P*-values for chi-squared tests are reported for categorical variables.
BMET total score ranges from 0-16 where a score ≤ 13 is suggestive of vascular cognitive impairment. The BMET O/M and EF/PS subscores each range from 0-8 where a lower score indicates worse cognition. The direction was reversed in regression analyses so that a higher value on the subscores corresponds to worse cognition.

Figures

Figure 1 Circular bar plot showing the results of cross-sectional univariate analyses for the association between 250 metabolic biomarkers and lacunar stroke



Figure 2 Heat map showing the results of cross-sectional univariate analyses for the association between 250 metabolic biomarkers and lacunar stroke, MRI markers, and cognitive impairment

(a) Main metabolites



(b) Lipoprotein subclasses and relative lipoprotein lipid concentrations